Results for tag: "Marginal Zone Lymphoma Drug"

Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin's lymphoma, a cancer of the lymphatic system. It is a slow-growing cancer that is usually found in the spleen, lymph nodes, or other organs. Treatment for MZL typically involves chemotherapy, radiation, and/or immunotherapy. Drugs used to treat MZL include monoclonal antibodies, such as rituximab, and targeted therapies, such as lenalidomide and ibrutinib. The MZL drug market is a subset of the larger lymphoma drug market. It is composed of drugs specifically designed to treat MZL, as well as drugs used to treat other types of lymphoma that may also be effective in treating MZL. The market is expected to grow in the coming years due to the increasing prevalence of MZL and the development of new treatments. Some companies in the MZL drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen, Merck, Novartis, and Pfizer. Show Less Read more